Chest
EditorialsBiomarkers in COPD: Are We There Yet?
References (15)
- et al.
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
Lancet
(2006) - et al.
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
Lancet
(1997) - et al.
C-reactive protein levels and survival in patients with moderate to very severe COPD
Chest
(2008) - et al.
Contemporary management of chronic obstructive pulmonary disease: scientific review
JAMA
(2003) - et al.
Users' guides to the medical literature: XIX. Applying clinical trial results: A. How to use an article measuring the effect of an intervention on surrogate end points: Evidence-Based Medicine Working Group
JAMA
(1999) - et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur Respir J
(2008) - et al.
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
Thorax
(2006)
Cited by (20)
D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation
2015, American Journal of the Medical SciencesEffects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial
2012, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :The complex inflammatory pathways involved in COPD have become the focus of drug development efforts in recent years [2,8,9]. Successful development of new therapeutic agents has been hampered to an extent by a lack of suitable local and systemic biomarkers of the pathogenic processes in COPD [1,6,10,11]. An ideal biomarker would be a direct indicator of the process being studied, be associated with a clinically important outcome such as mortality, be reproducible, easily measured and sensitive to effective interventions aimed at the target outcomes of interest in COPD [1,6,11].
Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial
2011, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :The efficacy signals that were evaluated in this study were directed at two possible actions of the drug in COPD. The first signal set looked at the ability of AZD1236 to inhibit the inflammatory response already documented in COPD using a panel of biomarkers thought to be relevant to the pathogenesis of the condition [27,28] and the second signal looked for inhibition of the elastase activity that MMP-12 is thought to exert. In a pre-clinical model of smoke-induced emphysema in the guinea pig, a combined MMP-9/MMP-12 inhibitor reduced serum TNF-α after 1 month’s therapy and the effect was maintained over the 6-months examined [11].
Biomarkers in COPD
2010, Pulmonary Pharmacology and Therapeutics8-hydroxy-2’-deoxyguanosine as a biomarker of oxidative stress in acute exacerbation of chronic obstructive pulmonary disease
2019, Turkish Journal of Medical SciencesC-reactive protein concentrations among crop and dairy farmers with stable chronic obstructive pulmonary disease
2017, Open Access Macedonian Journal of Medical Sciences
Both authors have received honoraria for speaking engagements from GlaxoSmithKline and AstraZeneca and for consultative services from GlaxoSmithKline.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
- 1
Dr. Sin is an Associate Professor of Medicine and a Canada Research Chair in COPD at the University of British Columbia, and a Senior Scholar with the Michael Smith Foundation for Health Research.
- 2
Dr. Man is a Professor of Medicine at the University of British Columbia.